참고문헌
- Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020;91:157-60.
- Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 2020;396:1595-606. https://doi.org/10.1016/S0140-6736(20)32137-1
- US Food and Drug Administration. Moderna COVID-19 vaccine [Internet]. Silver Spring (MD): FDA; 2021 [cited 2021 May 4]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine.
- US Food and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 vaccine [Internet]. Silver Spring (MD): FDA; 2021 [cited 2021 Dec 2021]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine.
- European Medicines Agency. EMA recommends COVID-19 vaccine Moderna for authorisation in the EU [Internet]. Amsterdam: EMA; 2021 [cited 2021 May 4]. Available from: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu.
- European Medicines Agency. EMA recommends first COVID-19 vaccine for authorisation in the EU [Internet]. Amsterdam: EMA; 2020 [cited 2021 Dec 27]. Available from: https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu.
- Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2: preliminary report. N Engl J Med 2020;383:1920-31. https://doi.org/10.1056/NEJMoa2022483
- Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med 2020;383:2439-50. https://doi.org/10.1056/NEJMoa2027906
- Teo SP. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. J Pharm Pract 2022;35:947-51. https://doi.org/10.1177/08971900211009650
- Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 2021;595:572-7. https://doi.org/10.1038/s41586-021-03653-6
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384:403-16. https://doi.org/10.1056/NEJMoa2035389
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603-15. https://doi.org/10.1056/NEJMoa2034577
- Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. N Engl J Med 2021;384:2259-61. https://doi.org/10.1056/NEJMc2103916
- Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur 2021;10:100208.
- Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nat Med 2021;27:2025-31. https://doi.org/10.1038/s41591-021-01527-y
- Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N Engl J Med 2022;386:492-4. https://doi.org/10.1056/NEJMc2119358
- Chu L, Vrbicky K, Montefiori D, et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nat Med 2022;28:1042-9. https://doi.org/10.1038/s41591-022-01739-w
- Falsey AR, Frenck RW Jr, Walsh EE, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med 2021;385:1627-9. https://doi.org/10.1056/NEJMc2113468
- Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020;383:2427-38. https://doi.org/10.1056/NEJMoa2028436
- Chu L, McPhee R, Huang W, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine 2021;39:2791-9. https://doi.org/10.1016/j.vaccine.2021.02.007
- Atmar RL, Lyke KE, Deming ME, et al. Heterologous SARS-CoV-2 booster vaccinations: preliminary report. medRxiv [Preprint] 2021 Oct 15. https://doi.org/10.1101/2021.10.10.21264827
- Munro AP, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 2021;398:2258-76. https://doi.org/10.1016/S0140-6736(21)02717-3
- Tani N, Chong Y, Kurata Y, et al. Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine. Vaccine 2022;40:2062-7. https://doi.org/10.1016/j.vaccine.2022.02.025
- Held J, Esse J, Tascilar K, et al. Reactogenicity correlates only weakly with humoral immunogenicity after COVID-19 vaccination with BNT162b2 mRNA (Comirnaty(R)). Vaccines (Basel) 2021;9:1063.
- Oyebanji OA, Wilson B, Keresztesy D, et al. Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents? Aging Clin Exp Res 2021;33:3151-60. https://doi.org/10.1007/s40520-021-01987-9
- Goel RR, Apostolidis SA, Painter MM, et al. Longitudinal analysis reveals distinct antibody and memory B cell responses in SARS-CoV2 naive and recovered individuals following mRNA vaccination. medRxiv [Preprint] 2021 Mar 6. https://doi.org/10.1101/2021.03.03.21252872
- Debes AK, Xiao S, Colantuoni E, et al. Association of vaccine type and prior SARS-CoV-2 infection with symptoms and antibody measurements following vaccination among health care workers. JAMA Intern Med 2021;181:1660-2. https://doi.org/10.1001/jamainternmed.2021.4580
- Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430-6. https://doi.org/10.1038/s41586-020-2521-4
- Eliakim-Raz N, Leibovici-Weisman Y, Stemmer A, et al. Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged ≥60 years. JAMA 2021;326:2203-4. https://doi.org/10.1001/jama.2021.19885
- Kruttgen A, Cornelissen CG, Dreher M, Hornef MW, Imohl M, Kleines M. Determination of SARS-CoV-2 antibodies with assays from Diasorin, Roche and IDvet. J Virol Methods 2021;287:113978.
- Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol 2020;38:1073-8. https://doi.org/10.1038/s41587-020-0631-z
- Hause AM, Baggs J, Marquez P, et al. Safety monitoring of COVID-19 vaccine booster doses among adults: United States, September 22, 2021-February 6, 2022. MMWR Morb Mortal Wkly Rep 2022;71:249-54. https://doi.org/10.15585/mmwr.mm7107e1
- Kadali RA, Janagama R, Peruru S, et al. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: a randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol 2021;93:4420-9. https://doi.org/10.1002/jmv.26996
- Ziemann M, Gorg S. Inability to work after Corona vaccination in medical staff. Dtsch Arztebl Int 2021;118:298-9. https://doi.org/10.3238/arztebl.m2021.0205
- Verbeke R, Lentacker I, De Smedt SC, Dewitte H. The dawn of mRNA vaccines: the COVID-19 case. J Control Release 2021;333:511-20. https://doi.org/10.1016/j.jconrel.2021.03.043
- Wec AZ, Wrapp D, Herbert AS, et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 2020;369:731-6. https://doi.org/10.1126/science.abc7424
- Pardi N, Hogan MJ, Naradikian MS, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 2018;215:1571-88. https://doi.org/10.1084/jem.20171450